MASIMO 2852 Kelvin Avenue Irvine, CA 92614 Tel: 949-250-9688 Fox: 949-250-9686

510(k) SUMMARY

FEB 1 9 2004

Submitted by:

Masimo Corporation

2852 Kelvin Ave

Irvine, CA 92614-5826

(714) 250-9688 FAX (714) 250-9686

Company Contact:

James J. Cronin, Vice President, Regulatory Affairs/Quality Assurance

Date Summary Prepared:

October 2, 2003

Trade Names

LNOP-TF-I Reusable Transflectance Sensor

Common Names

Pulse Oximetery Sensors

Classification Names

Oximeter (74DQA) (870.2700)

Cable, Transducer and Electrode (74DSA) (870.2900)

Substantially Equivalent Devices

Masimo SET Radical Pulse Oximeter with SatShareTM and LNOP series of Sensors and

Cables 510(k) Number - K000126

Nellcor Oximax Max-Fast Adhesive Forchead Sensor - 510(k) Number - K021089

Description

The Masimo series of oximetry sensors measure the light absorption of blood from two light emitting diodes (LED's). Oxygen saturated blood absorbs light differently than unsaturated blood. The amount of light absorbed by the blood is used to calculate the ratio of oxygenated hemoglobin to total hemoglobin in arterial blood. This filing includes the addition of 2 reusable sensors and a disposable sensor.

Intended use

The additional Masimo series of sensors are intended for continuous noninvasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO₂) and pulse rate (measured by an SpO₂ sensor) for adult, pediatric, and neonatal patients in hospitals, hospital-type facilities, mobile, and home environments.

Indications For Use:

The additional Masimo series of sensors are indicated for the following:

Reusable oximetry transflectance sensor intended for adults and pediatrics greater than 30 kg in hospitals, hospital-type facilities, mobile, and home environments.

Comparison to Predicate Devices:

The additional Masimo series of sensors all use the same theory and principle of operation as the predicate devices.

510(k) SUMMARY

D.	erformance	Data	and i	Conc	hielane
rı	44.1111. KUSA 114.15	прини	241164		111111111

Performance testing was conducted on adult volunteers. The additional sensor was compared to arterial blood samples analyzed on a laboratory CO-Oximeter. Accuracy (Arms) for the LNOP-TF-I sensor is \pm 2.0% SpO₂.

0029

—Masimo Cordoration...



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

FEB 1 9 2004

Mr. James Cronin Vice President, Regulatory Affairs/Quality Assurance Masimo Corporation 2852 Kelvin Ave. Irvine, CA 92614-5826

Re: K032551

Trade/Device Name: Masimo LNOP TF-1 Reusable Transflectance Sensor

Regulation Number: 21 CFR 870.2700

Regulation Name: Oximeter Regulatory Class: Class II Product Code: 74 DQA Dated: February 4, 2004 Received: February 5, 2004

Dear Mr. Cronin:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration

Page 2 – Mr. James Cronin

and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4646. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Chiu Lin, Ph.D.

Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

Indications for Use

K032551						
SET® Radical Pulse Oximeter with S	atShare™ and the Masimo Series of Sensors and	Cables				
dications For Use:						
The following additional Masimo Sensor is indicated for the continuous noninvasive functional oxygen saturation of arterial hemoglobin (SpO ₂) and pulse rate: Reusable oximetry transflectance sensor intended for adults and pediatrics greater than 30 kg in hospitals, hospital-typ facilities, mobile, and home environments.						
	Over-The-Counter Use (Per 21 CFR 807 Subpart C)	- 00ء				
RITE BELOW THIS LINE-CO	ONTINUE ON ANOTHER PAGE IF NE	EDED)				
(Division Sign-Off) Division Grauestraciology Con						
evices						
	AND/OR AND/OR AND/OR Concurrence of CDRH, Office of CDRH, O	SET® Radical Pulse Oximeter with SatShare™ and the Masimo Series of Scnsors and mo Sensor is indicated for the continuous noninvasive functional oxygen saturation of ate: Institute that is a sensor intended for adults and pediatrics greater than 30 kg in hospitals, home environments. AND/OR Over-The-Counter Use				